AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Merus N.V.'s COO & GC Silverman Peter B. makes significant trades on 2025-07-09 & 2025-07-10.
ByAinvest
Friday, Jul 11, 2025 4:16 pm ET1min read
Merus N.V. (MRUS) has disclosed that Chief Operating Officer and General Counsel, Peter B. Silverman, executed the following transactions on July 9 and 10, 2025. On July 9, Silverman acquired 6695 shares at $18.61 per share and subsequently sold the same number of shares at $55 per share. On the following day, he purchased 16,805 shares at $18.61 per share and sold an identical number of shares at $55 per share.
Merus NV (MRUS), a Netherlands-based biotechnology company focused on developing cancer therapeutics, has seen its stock price rise significantly in recent months. The company's stock has gained 29.9% over the past three months, fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab (MCLA-158), in combination with Merck’s Keytruda (pembrolizumab) [2].On July 9 and 10, 2025, Chief Operating Officer and General Counsel, Peter B. Silverman, executed a series of transactions involving Merus NV shares. On July 9, Silverman acquired 6695 shares at $18.61 per share and subsequently sold the same number of shares at $55 per share. On the following day, he purchased 16,805 shares at $18.61 per share and sold an identical number of shares at $55 per share [3].
The transactions indicate that Silverman bought a total of 23,550 shares at an average price of $18.61 per share and sold the same number of shares at an average price of $55 per share. This results in a total profit of $1,060,395 from the transactions.
Silverman's transactions come at a time when the company's stock has been performing well, driven by positive clinical trial results and the potential of its cancer therapeutics. However, it is essential to note that such transactions do not necessarily indicate a change in the company's outlook or the potential for future growth.
References:
[1] https://www.marketsmojo.com/stocks-analysis/merus-nv-1137942-210
[2] https://www.nasdaq.com/articles/mrus-stock-soars-30-3-months-after-phase-ii-cancer-study-success
[3] Merus NV's COO Executes Significant Share Transactions
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet